Reminder: Starting January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred brand status for Blue Cross and Blue Shield of Illinois, Blue Cross and Blue Shield of Montana, Blue Cross and Blue Shield of New Mexico, Blue Cross and Blue Shield of Oklahoma, and Blue Cross and Blue Shield of Texas Commercial formularies. (Novolin and Novolog will be the insulin products with preferred brand status for Exchange Affected Market formularies.)

Prime Perspective

Quarterly Pharmacy Newsletter from Prime Therapeutics LLC

Effective January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred status for Commercial and Exchange Market formularies.  Please see the attachment below for further processing instructions.

Effective January 1, 2015, Health Options will begin using Argus Health Systems to process claims.

Effective January 1, 2015, Magellan Medicaid Administration, Inc., d/b/a Magellan Health Services, will assume administrative operation of the Pharmacy Benefit Management (PBM) program for Tennessee CoverRx from the current administrating company, Express Scripts. At that same time, pharmacies will submit claims for payment through the new PBM system. The new system will provide point-of-sale (POS) claims processing.